Swedish Orphan Biovitrum: all 135 studies

Page 1 of 2. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.

• A Study of Avatrombopag in Adults With Aplastic Anemia Who Did Not Respond to, Cannot Receive, or Had Return of Disease After Standard TreatmentNot yet recruitingNCT07786922Phase 2/3
• Pacritinib Effectiveness in Real-world SettingsRecruitingNCT07774455
• Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country StudyRecruitingNCT07746895Phase 4
• A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)RecruitingNCT06782373Phase 2
• Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic LymphohistiocytosisCompletedNCT06047210Results posted
• An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog AlfaTerminatedNCT05856266Phase 4Results posted
• A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese PatientsCompletedNCT05744063Phase 4Results posted
• Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITPCompletedNCT05369208Phase 3Results posted
• A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell TransplantationCompletedNCT05148299Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)CompletedNCT05096403Phase 3Results posted
• Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLECompletedNCT05001737Phase 3Results posted
• Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With RuxolitinibCompletedNCT04884191Phase 2Results posted
• A Study to Evaluate Emapalumab in Japanese Healthy Volunteers.CompletedNCT04765553Phase 1Results posted
• Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.TerminatedNCT04731298Phase 2Results posted
• Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or RomiplostimCompletedNCT04638829Phase 4Results posted
• A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy IICompletedNCT04596540Phase 3Results posted
• Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 MonthsCompletedNCT04516967Phase 3Results posted
• A Study of SEL-212 in Patients With Gout Refractory to Conventional TherapyCompletedNCT04513366Phase 3Results posted
• PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without CancerTerminatedNCT04404361Phase 2Results posted
• Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.TerminatedNCT04324021Phase 2/3Results posted
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLHTerminatedNCT03985423Phase 2/3Results posted
• A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA PatientsCompletedNCT03811028Phase 1/2Results posted
• Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological CancersCompletedNCT03471078Phase 3Results posted
• A Study to Assess the Safety and Tolerability of SOBI003 in Pediatric MPS IIIA PatientsCompletedNCT03423186Phase 1/2Results posted
• Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical ProcedureTerminatedNCT03326843Phase 3Results posted
• Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic LymphohistiocytosisCompletedNCT03312751Phase 3Results posted
• A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)CompletedNCT03311854Phase 2Results posted
• A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)TerminatedNCT03265132Phase 3Results posted
• Evaluation of IFNγ and Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic LymphohistiocytosisCompletedNCT03259230Results posted
• Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI TherapiesCompletedNCT03103542Phase 4Results posted
• A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty ArthritisCompletedNCT03002974Phase 2Results posted
• A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal AntibodyCompletedNCT02069899Phase 2/3Results posted
• Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and ThrombocytopeniaTerminatedNCT02055781Phase 3Results posted
• Bioequivalence of Orfadin 20 mg Compared to Orfadin 10 mg Capsules.CompletedNCT01857362Phase 1Results posted
• Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic LymphohistiocytosisCompletedNCT01818492Phase 2/3Results posted
• Pacritinib Versus Best Available Therapy to Treat MyelofibrosisTerminatedNCT01773187Phase 3Results posted
• Taste and Palatability of Orfadin SuspensionCompletedNCT01734889Phase 1Results posted
• Bioequivalence of Orfadin Suspension Compared to Orfadin Capsules, and the Effect of Food on the Bioavailability of the SuspensionCompletedNCT01682538Phase 1Results posted
• Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell TransplantCompletedNCT01321541Phase 3Results posted
• Study to Characterize the Effect of Heparin on Palifermin ActivityCompletedNCT01163097Phase 1Results posted
• Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic InsufficiencyCompletedNCT00743483Phase 2Results posted
• A Study of Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy and Concurrent ChemotherapyCompletedNCT00626639Phase 1/2Results posted
• A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCTCompletedNCT00460421Phase 1Results posted
• A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple MyelomaCompletedNCT00434161Phase 3Results posted
• A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against DoxorubicinCompletedNCT00268853Phase 2Results posted
• Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) TransplantationCompletedNCT00189488Phase 2Results posted
• Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)CompletedNCT00109031Phase 3Results posted
• Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck CancerCompletedNCT00101582Phase 3Results posted
• Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00094861Phase 2Results posted
• BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)CompletedNCT00088530Phase 3Results posted
• An Efficacy and Safety Study of Subcutaneous Anakinra in Chinese Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD)WithdrawnNCT07706868Phase 4
• Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed PatientsActive, not recruitingNCT07116746Phase 2
• Assessment of Macrophage Activation syndromE in STill's Disease in ItalyCompletedNCT06992505
• Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog AlfaActive, not recruitingNCT06940830Phase 4
• Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)CompletedNCT06846515Phase 3
• A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa ProphylaxisActive, not recruitingNCT06752850Phase 4
• Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog AlfaActive, not recruitingNCT06716814Phase 3
• A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMFWithdrawnNCT06666335Phase 4
• Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia ACompletedNCT06579144Phase 1
• Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)CompletedNCT06439602Phase 3
• Assessment of Macrophage Activation syndromE in STill's DiseaseCompletedNCT06405152
• A Non-interventional, Post-Marketing Study to Describe Outcome of Nitisinone Treatment in HT-1 PatientsWithdrawnNCT06227429
• A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog AlfaCompletedNCT05817812Phase 3
• A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)Active, not recruitingNCT05814159Phase 3
• A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Active, not recruitingNCT05776472
• Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male SubjectsCompletedNCT05657613Phase 1
• Study to Evaluate the Safety, Tolerability, and PK of PacritinibCompletedNCT05552183Phase 1
• Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous GoutCompletedNCT05253833Phase 2
• Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout PatientsCompletedNCT05119686Phase 2
• Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of ≤6 MonthsWithdrawnNCT05046327Phase 3
• An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITPCompletedNCT04943042
• Psychometric Validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST)CompletedNCT04731701
• Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal ImpairmentCompletedNCT04646889Phase 1
• Single-dose AME Study With [14C]AR882 in Healthy Male SubjectsCompletedNCT04508426Phase 1
• A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplantTerminatedNCT04494061
• The Study is Designed to Evaluate Single Ascending Doses of AR882 in Healthy Adult MalesCompletedNCT04347005Phase 1
• Multiple Ascending Dose Study of AR882 in Healthy Adult Male VolunteersCompletedNCT04314986Phase 1
• A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint HealthCompletedNCT04293523
• Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout PatientsCompletedNCT04155918Phase 2
• Impact on French Physician's Haemophilia Treatment Management Decision Based on Systematic Joint ExaminationCompletedNCT04133883Not applicable
• rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia ACompletedNCT03951103
• Long-term Safety Study of Kineret® in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)CompletedNCT03932344
• An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia BCompletedNCT03901755
• A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in FranceCompletedNCT03655340
• Avatrombopag for the Treatment of Thrombocytopenia in Adults With Chronic Liver Disease Undergoing a ProcedureTerminatedNCT03554759
• Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and BCompletedNCT03276130
• A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia MyelofibrosisActive, not recruitingNCT03165734Phase 3
• A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy VolunteersCompletedNCT03103568Phase 1
• A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or BCompletedNCT03055611
• Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor ProductsCompletedNCT02976753
• Kineret in the Treatment of Rheumatoid ArthritisCompletedNCT02915094
• To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy SubjectsCompletedNCT02823171Phase 1
• Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy SubjectsCompletedNCT02808455Phase 1
• To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy SubjectsCompletedNCT02807207Phase 1
• Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy SubjectsCompletedNCT02807116Phase 1
• PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy SubjectsCompletedNCT02807077Phase 1
• To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy SubjectsCompletedNCT02807051Phase 1
• Investigate Absorption, Metabolism, Excretion, and Mass Balance of PacritinibCompletedNCT02803762Phase 1
• Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory CancerWithdrawnNCT02800889Phase 1
• Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy SubjectsCompletedNCT02765724Phase 1

← Swedish Orphan Biovitrum overview and focus areas